9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 retinoic acid responsive elements by 源��꽦洹� et al.
©2
006
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
[Cancer Biology & Therapy 5:6, 586-592, June 2006]; ©2006 Landes Bioscience
586 Cancer Biology & Therapy 2006; Vol. 5 Issue 6
Yoon Soo Chang1
Jae Yong Cho1
Hyun A Cho1
Hyung Jung Kim1,2
Joon Chang1,2
Chul Min Ahn1,2
Sung Kyu Kim1,2
Se Kyu Kim1,2,3,4
Department of 1Internal Medicine, 2Institute of Chest Diseases, 3Brain Korea 21
Project for Medical Sciences and 4Cancer Metastasis Research Center; Yonsei
University College of Medicine; Seoul, Korea
*Correspondence to: Se Kyu Kim; Department of Internal Medicine; Yonsei
University College of Medicine; C.P.O Box 8044; Seodaemun-ku, Shinchon-dong
134, Seoul, 120-752 Korea; Tel.: +82.2.2228.1954; Fax: +82.2.393.6884;
Email: sekyukim@yumc.yonsei.ac.kr
Received 11/22/05; Accepted 03/05/06
Previously published online as a Cancer Biology & Therapy E-publication:
http://www.landesbioscience.com/journals/cbt/abstract.php?id=2658
KEY WORDS
insulin-like growth factor, insulin-like growth factor
binding protein-3, 9-cis retinoic acids, retinoic acid
receptor-β, non-small cell lung cancer
ABBREVIATIONS
DR direct repeat
IGF insulin-like growth factor
IGFBP-3 insulin-like growth factor binding 
protein-3
NSCLC non-small cell lung cancer
RARE retinoic acid responsive element
RAR retinoic acid receptor
ACKNOWLEDGEMENTS
Supported in part by Korea Research Foundation
Grant funded by Korea Government (MOEHRD,
Basic Research Promotion Fund) (KRF-2005-003-
E00101) and by the Korea Science and Engineering
Fund through the Cancer Metastasis Research
Center at Yonsei University, Seoul, Korea.
Research Paper
9-cis Retinoic Acid Induces Insulin-like Growth Factor Binding Protein-3
through DR-8 Retinoic Acid Responsive Elements
ABSTRACT
Retinoic acids, which have shown potential chemopreventive and therapeutic activities
for several neoplastic diseases in vitro, modulate the growth-promoting and anti-apoptotic
activities of insulin-like growth factors (IGFs), in part by influencing the expression of
insulin-like growth factor binding protein-3 (IGFBP-3). This study sought to investigate the
effect of 9-cis retinoic acid (9cRA) on the expression of IGFBP-3 and the underlying
mechanisms involving retinoic acid receptor-β (RAR-β).The pharmacologic activity of
9cRA was characterized by monitoring target modulation as well as by evaluating the
underlying mechanisms in NSCLC cells. Treatment of 9cRA inhibited proliferation of a
part of NSCLC cell lines including H460 cells in clinically-achievable concentrations and
induced IGFBP-3 expression in dose- and time-dependent manners. Transient transfection
with a reporter constructs driven by the human IGFBP-3 gene promoter indicated that
9cRA induces gene expression via the -534 to -445 region (relative to translation start
site) of the IGFBP-3 promoter. Unilateral deletion and site-directed mutagenesis identified
a retinoic acid responsive element (RARE), a direct repeat of two GGGTCA-related hexa-
nucleotides separated by just 8 bp (DR-8-type response element). A cotransfection assay
with a RAR-β expression vector potentiated (and with siRNA for RAR-β, diminished) the
effect of 9cRA on IGFBP-3 expression. IGFBP-3 gene expression by 9cRA is mediated by
a distinct DR-8 RARE located in the proximal region of the IGFBP promoter and involves
the RAR-β, a putative tumor suppressor in NSCLC.
INTRODUCTION
Retinoids are one of the most extensively studied agents in the secondary and tertiary
chemoprevention of lung cancer. A common problem with these chemicals is pan-retinoid
toxicity, yet numerous natural and synthetic retinoids—effective inhibitors of tumor cell
growth in vitro and in vivo and selective for the different retinoid receptor isotopes—have
been generated that circumvent pan-retinoid toxicity. The tumor-suppressive activity of
selective retinoids and rexinoids have been established preclinically, and emerging clinical
trials are supportive of the chemotherapeutic and chemopreventive potential of these
compounds in multiple oncological indications, with reduced toxicity.1
One recent chemopreventive trial, which randomized former smokers to 13cRA plus
α-tocopherol, 9cRA, or placebo in an attempt to reverse premalignant lesions with the
desired biomarker, retinoic acid receptor-β (RAR-β), being upregulated in bronchial
epithelium, showed that administration of 9cRA decreased the percentage of subjects with
detectable squamous metaplasia in biopsy sites and increased RAR-β expression.2 Although
RAR-β is effectively upregulated by 9cRA in bronchial epithelium, data implicating main-
tenance of RAR-β intratumorly in NSCLC patients showed a poorer prognosis have cast
RAR-β in a less favorable light.1,3 Retinoid refractoriness, in terms of inducing RAR-β
expression or apoptosis with treatment of retinoids, is attributable, at least partially, to
aberrant promoter methylation and histone H3 acetylation. One study showed retinoid
receptor function to be intact in the t-RA-refractory malignant HBE cell line, however,
suggesting that the defect in retinoid signaling in this lung carcinogenesis model was not
intrinsic to the retinoid receptors.4 Such findings indicate the urgent need to discover a
cellular mediator of chemoprevention of retinoic acids other than RAR-β.
Insulin-like growth factor (IGF) binding proteins (IGFBPs), composed of 216 to 289
amino acids and representing a major reservoir of circulating IGFs, mobilize IGFs to
peripheral tissues and regulate their biologic activities.5 IGFBP-1, -2 and -4 traverse the
endothelial barrier and carry IGFs into peripheral tissues. Whereas IGFBP-3, the most
abundant such binding protein in circulation, can reach 150 kD when bound to IGF-I,
cannot penetrate endothelial cells, and has been implicated in regulating the content of
 
www.landesbioscience.com Cancer Biology & Therapy 587
IGFs in circulation.5,6 IGFBP-3 regulates IGF-1 bioactivity by
sequestering IGF-1 away from its receptor in the extracellular
milieu, thereby inhibiting the critical role of IGFs in cellular growth,
differentiation, transformation, and apoptosis.5,7,8 Besides its
IGF-I-dependent function, IGFBP-3, like IGFBP-1 and IGFBP-5,
has IGF-I-independent anti-proliferative and pro-apoptotic effects.9
The bioactivity of IGF system is modulated by retinoids, which
not only decreases directly the level of IGF-110 but also increases
IGFBP-3.11,12 IGFBP-3, in turn, mediates a wide variety of growth
suppression signals, including retinoic acid. Several findings further
suggest that IGFBP-3 might be a good candidate as a surrogate
marker of chemoprevention. These include a negative correlation
between serum IGFBP-3 levels and various solid cancer risks;13 an
association between expression of IGFBP-3 and prognosis of stage I
NSCLC patients;14,15 and a protective role of IGFBP-3 against the
effects of systemic IGF-I,8 which has been implicated in the devel-
opment of lung cancer. Thus, an urgent need exists for an effective
modality inducing IGFBP-3 expression. The chemotherapeutic and
chemopreventive potentials of retinoids and rexinoids might also
originate, in part, from induction of IGFBP-3.16 Yet the mechanism
by which IGFBP-3 gene transcription is stimulated by retinoic acids
has not been well-studied.
It is known that transcriptional activation by retinoids is mediated
through two families of nuclear hormone receptors, the retinoic acid
receptors, the RARs and the retinoid X receptors (RXRs). Three
distinct RXR and RAR genes have been identified, and, of these
nuclear hormone receptors, RAR-β is considered to be a tumor
suppressor gene in NSCLC.17-19 The retinoic acid receptors are
ligand-dependent transcription factors that bind to cis-acting DNA
sequences called retinoic acid responsive elements (RAREs) and
retinoid X responsive elements (RXREs), located in the promoter
region of their target genes.20 In this study, we report that IGFBP-3
gene expression by 9cRA involves RAR-β and is mediated by a
distinct DR-8 responsive element located in the proximal region of
the IGFBP-3 promoter.
MATERIALS AND METHODS
Chemicals, cell culture and treatment. 9cRA, (E)-4-[2-(5,6,7,8-
tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic
acid (TTNPB), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenbyl tetrazolium
bromide (MTT), anti-β-actin antibody and other chemicals were obtained
from the Sigma Chemical Company (St. Louis, MO, USA) unless otherwise
stated. Anti-IGFBP-3, anti-RAR-β, and anti-RXR-β antibodies and siRNA
for RAR-β were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). StealthTM RNAi Negative Control Duplexes, lipofectamineTM
2000 were purchased from Invitrogen (Carlsbad CA, USA). Human
NSCLC cell lines used in this study (NCI-H596,- A549, -H460, -H1299
and COS7) were purchased from the American Type Culture Collection
(Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented
with 10% fetal calf serum (FCS; Life Technologies, Inc., Gaithersburg, MD,
USA). For treatment of each retinoic acid derivative, cells were maintained
prior to harvest by splitting and incubation in RPMI-1640 medium supple-
mented with 2% FCS. To determine the effects of 9cRA on NSCLC cell
proliferation, the NSCLC cell lines were plated at concentrations of 1 X 103
cells per well in 96-well plates. The next day, cells were treated with various
titers of 9cRA and then incubated in 2% RPMI-1640 medium for the assay
period. At the end of the assay period, the proliferation of treated cells was
measured by using the MTT assay, as previously described elsewhere. Six
replicate wells were used for each assay; data from replicate wells are presented
as mean values with 95% confidence intervals (CIs). Three independent
experiments were performed with similar results; representative results of one
experiment are presented.
Soft agar colony formation assay. A colony formation assay was done
using 24-well plates. Each well contained 1 mL of 0.5% agar in RPMI-1640
medium supplemented with 2% FCS as the bottom layer, 1 mL of 0.35%
agar in 2% RPMI-1640 medium and 3,000 cells as the top layer with or
without 500 nM 9cRA. Cultures were maintained under standard culture
conditions. The number of colonies was determined with an inverted
phase-contrast microscope at X 100 magnification; a group of >10 cells was
counted as a colony. The data are means ± SE of four independent wells at
optimum time of 14 days after the start of cell seeding.
Analysis of gene expression. Western blot analysis was performed by the
standard procedure, employing antibodies raised against human RAR-β,
human IGFBP-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
β-actin (Sigma). For detection of the intended protein, 30 to 50 µg of total
protein was size fractionated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions, transferred to a
nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA),
and blocked with 5% nonfat dry milk in Tris-buffered saline-Tween (20
mM Tris HCl, pH 7.6; 150 mM NaCl; 0.1% Tween-20). Membranes were
incubated with primary antibodies (Santa Cruz Biotechnology) overnight at
4˚C and then with horseradish peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology) for 1 hr at room temperature. Immunoreactive
proteins were detected using an enhanced chemiluminescence (ECL) kit and
Hyperfilm ECL (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA).
Relative amounts of the proteins of interest were determined using the
ScionImage® software.
RNA preparation and semi-quantitative RT-PCR. Total cellular RNA,
isolated from NSCLC cells using TRIzol (Invitrogen), was reverse tran-
scribed and amplified using gene-specific primers and the SuperscriptTM
One-Step RT-PCR System with PlatinumTM TaqDNA Polymerase
(Invitrogen). The following primer pairs were used: IGFBP-3 sense, 5'-ACC
CCC TCC ATT CAA AGA TAA TCA-3', IGFBP-3 antisense, 5'-ACT TAT
CCA CAC ACC AGC AGA AGC-3'; RAR-β sense, 5'-ATG ACT TTC
TCA GAC GGC CTT ACC-3', RAR-β antisense, 5'-CCT TTA GCA
CTG ATG CTA CGG AGA-3'; GAPDH sense, 5'-TGG GTG TGA ACC
ATG AGA AGT ATG-3', GAPDH antisense, 5'-GTT TTT CTA GAC
GGC AGG TCA GGT-3'. Cycling conditions were 1 cycle of 50˚C for
30 min; 1 cycle of 94˚C for 2 min; and 32 cycles of 94˚C for 30 sec, 60˚C
for 30 sec, and 72˚C for 1 min.
Plasmid preparation. A 1.9-kb IGFBP-3 promoter and its deletion
mutants pGL2-∆1600 and pGL2-∆1675, subcloned to the luciferase
reporter vector pGL2-basic (Promega Corp., Madison, WI, USA), were
generous gifts from Dr. Oh Y (Oregon Health & Science University,
Portland, OR, USA). Reporter vector nomenclature, which specifies the
number of nucleotides removed from the 5'-end of pGL2-IGFBP-3, was
adopted from Walker et al.21 pGL2-∆862 was prepared from an oligo
corresponding to nucleotides -1064 to -64 (relative to the translation start
site designated +1) of the IGFBP-3 promoter generated by PCR with the
following primers: sense, 5'-GAG ATA AGC TTG AAT CCC AAC GC-3';
anti-sense, 5'-GCG AAG CTT TGG AAT CCA GGC A-3'. The same
method was used to prepare pGL2-∆1393 (-534 to -64; sense primer,
5-GTA TGC AAG CTT CCC CGA CAC C-3'; anti-sense primer, 5'-GCG
AAG CTT TGG AAT CCA GGC A-3') and pGL2-∆1482 (-445 to -64;
sense primer, 5'-GGT GCA AGC TTG GCC AGG AGT-3'; anti-sense
primer, 5'-GCG AAG CTT TGG AAT CCA GGC A-3'). Oligos were
subcloned into the HindIII site of the pGL2-Basic vector.
pGL2-∆1393 was used as a single-stranded DNA template for the produc-
tion of mutant pGL2-∆1393(R) with the primer AAG GGG TAA GGG
CGG CGG AAA AAA GGA GAT CGG GGG TG and its reverse sequence.
pGL2-∆1393(F) was generated using CAC CCC GAG AGC GGA AGA
AAA AAG GGC GGC GGG GTC AA-5' and its reverse sequence.
pGL2-∆1393(B) was generated using pGL2-∆1393(R) and the same primer
set as for pGL2-∆1393(F). pcDNA™3.1D/V5-His-TOPO® was purchased
from Invitrogen, and a full-length cDNA encoding RAR-β was inserted
according to the manufacturer’s instructions with the following primers:
5'-CAC CAT GGT TGA CTG TAT GGA T-3' and 5'-CTA GTT TCT
GGT TGC ATG AAA TG-3'. Induction of RAR-β was confirmed by
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Western blot analysis of COS7 and H460 cells transfected with
pcDNA™3.1D/V5-His- TOPO®-RAR-β.
Luciferase assay. H460 and COS7 cells were transiently transfected with
lipofectamine-2000 reagent according to the manufacturer’s instructions
(Invitrogen). Cells from each line were seeded at a density of 5 x 104
cells/well in 24-well plates. At 70% confluence, cells were transfected with
200 ng/well of luciferase reporter plasmid, 30 ng/well of CMV-β-gal control
vector (GibcoBRL), and either pcDNA™3.1D/V5-His-TOPO®-RAR-β
or siRNA for RAR-β in serum-free RPMI-1640 medium.
After 6 hr, the medium was changed to RPMI-1640 supple-
mented with 10% FCS. Cell lysates were collected for
luciferase assay 48 hr after transfection. Transfections were
performed in triplicate and experiments repeated at least
three times. Luciferase activity was measured according to
the manufacturer’s instructions (Promega) and normalized
against β-gal activity.
Electrophoretic mobility shift assay. Three double-
stranded 28-mer pairs (bp -488 to -461 from mRNA cap
site), corresponding to wild- or mutant-type RARE, were
synthesized by Genotech, Inc. (Daejun, Korea). The wild-
type oligomer consisted of 5'-GAA GGG GTA AGG GCG
GCG GGG TCA AGG A -3' and its reverse complement,
while the mutant-type was 5'-GAA GAA AAA AGG GCG
GCG AAA AAA AGG A-3' and its reverse complement.
These oligomers were end-labeled with [α-32P]-ATP with a
T4 polynucleotide kinase (Promega) according to the manu-
facturer’s instructions.
H460 crude nuclear extract preparation and EMSA were
performed as previously described.19 Briefly, 5 ug of purified
nuclear protein extracts were incubated in 20-µl reaction
mixtures (20 mM HEPES, pH 8.4; 100 mM KCl; 20% glyc-
erol; 0.1 mM EDTA; 50 ng/ml poly dA-dT; 0.05% NP-40;
1 mg of bovine serum albumin, BSA) at room temperature
for 10 min prior to addition of 0.2 ng of radiolabeled
oligonucleotide probe. Doses of wild- or mutant-type RARE
consensus oligomer (Promega) were added for competition
assays. After 20 min of room temperature incubation, samples
were separated on 5% acrylamide gels in 0.5X Tris-borate-
EDTA buffer. For EMSA supershift studies, 1 ug of polyclonal
RAR-β or RXR-β antibodies (Santa Cruz Biotechnology) or,
as a control, polyclonal HA antibody (Santa Cruz
Biotechnology) were added for 30 min of incubation following
the standard binding reaction. Gels were transferred, dried,
and exposed to Hyperfilm ECL (Amersham Pharmacia
Biotech).
Statistical analysis. For colony formation assay, Mann-
Whitney U test was used to examine the differences in colony
numbers between treatment groups. Comparisons of relative
levels of luciferase activity among the different transfections
were conducted using Kruskal-Wallis H test, followed by
Mann-Whitney U test for comparison of relative values
between groups. All statistical tests were two sided. p < 0.05
was considered statistically significant.
RESULTS
9cRA increases IGFBP-3 and RAR-β expression. First,
to investigate the effect of 9cRA on the anchorage dependent
growth of NSCLC cells, we treated NSCLC cells with indi-
cated dose of 9cRA for 24 hr to 48 hr and performed MTT
assay. 9cRA did not influence on the proliferation of A549
cells and H1299 cells, whereas inhibited proliferation in
H596 and H460 cells (representative data are shown in
Fig. 1). Figures 2A and B showed that treatment of 500 nM
9cRA inhibited the anchorage-independent growth of H460
NSCLC cells. For controls, 19 ± 2.1 (mean ± SE of four
wells) colonies per field were counted compared with 8 ± 0.6 colonies per
field counted in 9cRA treated wells (Fig. 2B). Compared with control cells,
treatment of 500 nM 9cRA results in 59.7% inhibition of colony formation
(Fig. 2B; p < 0.046, Mann-Whitney U test).
To elucidate whether 9cRA is involved in the regulation of IGFBP-3
gene expression, we examined the effect of 9cRA on expression of the
IGFBP-3 gene protein in vitro using H460 NSCLC cells cultured at various
concentrations and times. As shown in Figure 3A, 9cRA increased IGFBP-3
Figure 1. Effect of 9cRA on the proliferation of NSCLC cells. (A) NCI-H1299, (B) -H596,
(C) -A549 and (D) -H460 NSCLC cells were treated with vehicle or indicated concentration
of 9cRA and colorimetric MTT assays were then performed as described in “Materials and
Methods.” Results are expressed relative to the density of cells incubated in the vehicle
alone. Each value is the mean (± SD) from eight identical wells. Each experiment was
repeated three times. (Solid line, 24 hr treatment; dashed line, 48 hr).
Figure 2. Soft agar colony formation assay in H460 cells treated with 500 nM 9cRA or
control (vehicle only). (A) Representative photographs from three independent experiments
taken under an inverted phase-contrast microscope at X100 magnification. (B) Quantitative
analysis of soft agar colony formation of H460 cells treated with 9cRA or vehicle. Columns,
mean of four independent wells in two weeks incubation from the start of cell seeding;
bars, SE.
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expression in a dose-dependent manner until it reach 500 nM, with a
maximum 3.4-fold induction reached at 48 h of exposure to 500 nM 9cRA.
Reverse-transcribed mRNA was obtained from cells following the indicated
conditions, and the results of subsequent PCR are shown in Figure 3B.
High 9cRA concentration in the culture medium consistently induced an
increase in IGFBP-3 mRNA. 9cRA also increased RAR-β protein and
RAR-β mRNA levels at similar concentrations and times (Fig. 3A and B).
The 9cRA-mediated induction suggests the involvement of RAR/RXR in
IGFBP-3 gene activation, although analysis of the 9cRA effects does not
allow discrimination between the relative involvement of RAR and RXR
receptors in the activation of IGFBP-3 expression. To elucidate whether
RARs play a role in IGFBP-3 gene expression, the synthetic RAR-specific
agonist TTNPB was used. As shown in Figure 3C, TTNPB increased
IGFBP-3 protein expression in a dose-dependent manner. At the lower
concentration (0.1 to 10 nM), this effect was three orders of magnitude
higher than those observed with 9cRA.
9cRA increases IGFBP-3 gene expression at the transcriptional level.
To investigate the underlying mechanisms in which 9cRA increases
IGFBP-3 gene expression, H1299 NSCLC cells were transiently transfected
with a pGL2 luciferase reporter vector, driven by the wild-type IGFBP-3
promoter and its serial deletion mutants (Fig. 4A and B), and then treated
with 9cRA. Selection for H1299 cells was based on a previous experiment
that showed these cells to have lower levels of endogenous RAR-β and high
transfection efficiency compared to other NSCLC cell lines.20 As shown in
Figure 5, pGL2-∆862 exhibited a 2.5-fold induction of promoter activity by
9cRA. When a unilateral deletion construct carrying the -534 to -64 region
of the IGFBP-3 promoter (pGL2-∆1393) was introduced, the inductive
effect of 9cRA was similar to that of pGL2-∆862, whereas further deletion
of the promoter region to -445 bp (pGL2- ∆1482) abolished the inductive
effect of 9cRA. These results indicate that 9cRA acts on IGFBP-3 expression
at the transcriptional level and further suggest the presence of a retinoid
responsive region between -534 and -445 in the proximal IGFBP-3 pro-
moter.
9cRA activates IGFBP-3 promoter activity via RAR-β. In order to
determine those transcription factors critical for 9cRA-induced IGFBP-3
gene expression, H460 cells were transfected with either siRNA for RAR-β
or a RAR-β expression vector under the influence of 500 nM 9cRA or the
vehicle for 48 hr. Treatment with siRNA for RAR-β decreased IGFBP-3
expression, while the RAR-β expression vector potentiated 9cRA induce-
ment of IGFBP-3. Transfection with the RAR-β expression vector in the
absence of 9cRA also induced IGFBP-3, although not at a level comparable
to that for the combined treatment with 9cRA and the RAR-β expression
vector (Fig. 6A).
To further elucidate RAR-β involvement in
IGFBP-3 gene activation, pGL2-∆1393 containing a
putative RARE within the IGFBP-3 gene promoter (-534
to -445) was transfected into H1299 NSCLC cells. These
cells were tested under the effects of siRNA for RAR-β and
a RAR-β expression vector plus 9cRA (Fig. 6B). IGFBP-3
promoter activity was enhanced when cells were cotrans-
fected with RAR-β and decreased with siRNA for RAR-β.
In contrast, 9cRA in the presence of either siRNA resulted
in marginal stimulation of IGFBP-3 promoter activity.
Figure 3. Induction of IGFBP-3 and RAR-β in response to 9cRA and TTNPB.
H460 NSCLC cells were treated with the indicated doses of 9cRA or vehi-
cle for 48 hr. Whole cell extracts were prepared and analyzed by
immunoblot (A). mRNA expression was evaluated by semi-quantitative
RT-PCR (B). Expression of IGFBP-3 and RAR-β after treatment with TTNPB was
evaluated by Western blot (C). The experiment was repeated three times
with identical results. Actin and GAPDH were used for equal dose control.
S.M., DNA size marker;   , 42 kD IGFBP-3;    , glycosylated form of IGFPB-3.
Figure 4. Sequence and schematic diagram depicting the
human IGFBP-3 promoter used in this study. Sequence
analysis of IGFBP-3 promoter shows a putative DR-8 RARE
approximately 484 bp 5' to the translation start site (A).
This approximately 1.9-kb portion of the human IGFBP-3
promoter also includes a cluster of 11 p53 sites, five Yin and
Yang-1 (YY1) sites, a GC-rich/Sp-1 site, and two consensus
AP2 sites. The DR-8 RARE is deleted in pGL2-∆1482, as is
the entire DR-8 RARE in pGL2-∆1393 (B). Numbering of
plasmid follows the designation of Walker et al.21
590 Cancer Biology & Therapy 2006; Vol. 5 Issue 6
9cRA Induces IGFBP-3 via DR-8 RARE
Taken together, these data demonstrate the involvement of RAR-β in the
9cRA-induced transactivation of the IGFBP-3 gene.
Identification of retinoid responsive element in IGFBP-3 promoter.
Sequence analysis of the IGFBP-3 promoter indicated a putative retinoid
responsive element (RARE) composed of a DR-8 sequence (two directly-
repeated TGACCT motifs separated by eight nucleotides; GGGTAA
gggcggcgGGGTCA, nucleotides -484 to -465 upstream of the transcription
start site) (Fig. 7A). Owing to data in the previous section suggesting
involvement of RAR-β in IGFBP-3 gene transactivation, we suppose this
putative responsive element to be a RARE. To determine whether this
element mediates the retinoid response of the IGFBP-3 gene, three modified
IGFBP-3 promoter plasmid constructs were transfected into H1299
NSCLC with 9cRA. The first construct corresponded to pGL2-∆1393 of
the IGFBP-3 promoter mutated to include the 5' GGGTCA motif of the
putative RARE [pGL2-∆1393(F)]. When compared to the wild-type
construct (pGL2- ∆1393), mutation of this element in the RARE sequence
led to a 12% reduction in the 9cRA inductive effect. In the second construct,
mutation in the 3' motif of the putative RARE [pGL2-∆1393(R)] of the
promoter also decreased 9cRA-mediated induction (41.1%). In the third
construct, mutations introduced in the GGGTCA-like motif [pGL2-
∆1393(B)] of the IGFBP-3 promoter further abolished 9cRA-mediated
induction (70.5%; Fig. 7B). Our data suggest that the putative DR-8
RARE, located from -484 to -465 from the mRNA start site, participates in
9cRA-induced IGFBP-3 expression.
To further investigate the involvement of synthetic retinoic acids in the
nuclear translocation of RAR-β and RXR-β, we performed Western blot
analysis with a nuclear extract of H460 cells treated with the indicated doses
of 9cRA, 13cRA, and TTNPB. Very low induction of RXR-β expression was
observed in nuclear extracts from the synthetic retinoic acid derivatives
treatment group, whereas RAR-β was strongly induced by 9cRA and 13cRA
treatment (Fig. 8A).
Gel shift analysis was performed, showing the RARE to be an essential
region for 9cRA-induced IGFBP-3 promoter activity in H460 NSCLC cells.
For this study, we designed a 28-mer oligonucleotide (-488 to -461; WT)
spanning the putative RARE in the IGFBP-3 promoter. When the nuclear
extract from H460 cells was used, a DNA:protein complex was formed
(Fig. 8B). Specificity of binding was verified by competition assays; in which
each complex was successfully out-competed by increasing concentrations
of unlabeled wild-type RARE consensus oligonucleotides (S.C.). Complexing
was not abolished by treatment with unlabeled mutant RARE consensus
oligonucleotides (N.C.) (Fig. 8B). We then used polyclonal antibodies raised
against RAR-β or RXR-β to demonstrate that complexes indeed contained
RAR-β. RAR-β antibody (Fig. 8C, lanes 2), but not a RXR-β and a control
(anti-HA) antibodies (Fig. 8C, lane 3 and 4), led to disappearance of the
complex.
DISCUSSION
With the advent of novel targeted agents such as COX-2 inhibitors,
farnesyl transferase inhibitors, and epidermal growth factor receptor
tyrosine kinase inhibitors, there has been a push to consider molecular
targeted approaches to NSCLC and the development of appropriate
surrogate markers for chemoprevention. Despite substantial advances
in chemoprevention of breast, colon, bladder, and head/neck cancers,
the prevention of lung cancer is still a distant goal. This is in part due
to a lack of appropriate surrogate markers suitable for long-term
follow-up care. RAR-β, regarded as a tumor suppressor in upper
aerodigestive tract cancer, is one of the frequently-used surrogate
markers in chemoprevention trials. One recent large-scale chemo-
preventive trial sought to reverse detectable squamous metaplasia in
the bronchial epithelium of former heavy smokers with 9cRA or
13cRA plus α-tocopherol. The study showed that administration of
9cRA reduced the percentage of subjects with detectable squamous
metaplasia and led to a statistically significant increase in RAR-β
Figure 5. Luciferase assay of serial deletion mutants of IGFBP-3 promoter
with or without treatment of 9cRA. 9cRA treatment induces IGFBP-3 promoter
activity in the pGL2-∆1393 reporter vector, which contains a putative RARE.
pGL2-∆ 1482 and -∆1600, in which the 5' element of the putative RARE and
the entire putative RARE is deleted respectively, revealed a blunted response
to 9cRA. Each experiment was repeated at least three times with identical
results. RLU, relative luciferase activity.
Figure 6. Treatment with siRNA for RAR-β decreased 9cRA induction of
IGFBP-3; siRNA for RAR-β expression vector potentiated this induction.
H460 NSCLC cells were treated with siRNA for RAR-β or a RAR-β expression
vector under the influence of 500 nM 9cRA or the vehicle for 48 hr. Whole
cell extracts were prepared and analyzed by immunoblot (A). Promoter
activity of pGL2- ∆1393 was measured after treatment with siRNA for RAR-β
or the RAR-β expression vector under the influence of 500 nM 9cRA or
vehicle (B). Each experiment was repeated at least three times with identical
results. RLU, relative luciferase activity.
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expression in the biopsy site. Although RAR-β was effectively upreg-
ulated by 9cRA in the bronchial epithelium of former smokers, data
implicating maintenance of RAR-β intratumoraly in stage I NSCLC
in individuals with a poorer prognosis3 has shed some doubt on
these results.1 Consecutive reports that elevated IGF-1 and decreased
IGFBP-3 in circulation are related to the development of various
solid cancers, however, not only bolster IGFBP-3 as a good candidate
for surrogate marker but also urge the development of effective ways
to up-regulate IGFBP-3.
Here, we demonstrated that the expression of IGFBP-3 in
NSCLC cells was induced by the pan-retinoic acid receptor agonist,
9cRA, and that administration of this agent decreased frequency of
metaplasia in the bronchial epithelium of former heavy smokers.2
Induction of IGFBP-3 expression by 9cRA occurs at the transcriptional
level, as measured by semi-quantitative RT-PCR. Concurrence of
semi-quantitative RT-PCR and Western blot in the expression of
IGFBP-3 and RAR-β indicated that 9cRA activates IGFBP-3 gene
transcription, supporting the previous findings that a major consensus
sequence for retinoic acid may be present in the promoter region of
the IGFBP-3 gene.24
By using a RAR-selective agonist (TTNPB), we demonstrated that
RAR-β expression was induced by 9cRA through a RAR-dependent
signaling pathway and that RAR-β induction was correlated with
IGFBP-3 induction. Further, expression of IGFBP-3 is mediated by
RAR-β, as blocking of RAR-β expression by siRNA for RAR-β
diminished expression of IGFBP-3. When H1299 cells were trans-
fected with cDNA encoding RAR-β, the promoter activity of
IGFBP-3 was increased; it was further
augmented in the presence of 9cRA.
Transfection of H460 cells with siRNA
for RAR-β not only inhibited
9cRA-induced IGFBP-3 expression, but
also IGFBP-3 promoter activity, indicat-
ing that RAR-β is directly involved in the
mediation of IGFBP-3 induction by
9cRA. A connection between IGFBP-3
and RAR-β defines the signal intersection
between the retinoid and IGF systems in
cell growth regulation and suggests why
the loss of RAR-β might be critical in
NSCLC carcinogenesis and progression.
Several regulatory elements—a cluster
of 11 p53 consensus binding sites; five
consensus Yin and Yang-1 (YY1) sites; a
sequence cluster comprised of a GC-rich/
Sp1 site, AP-2 site overlapping a GA-box,
and p300 DNA binding site—are found
in the promoter of IGFBP-3.21 Earlier
work using rat IGFBP-3 promoter identi-
fied the major consensus sequences that
could be activated by retinoic acid as an
AP-2 and an Oct site, which locate from
-78 to -71 and at -612, respectively, relative
to the transcription start site. There are,
however, minor differences between human and rat IGFBP-3
promoter sequences. Between the human and rat IGFBP-3 promoters,
there is 65% sequence conservation within 1.2 kb of the promoter,
and the rat IGFBP-3 promoter lacks a putative RARE in the
5'-untranslated flanking region.24 Computer-based simulation using
the transcription element search system (TESS; http://www.cbil.
upenn.edu/tess) algorithm and our experiment using serial deletion
mutants cloned into the pGL2-reporter vector showed that a RARE
consisting of two half-sites arranged as a direct repeat with an 8-bp
spacer (DR-8) is located from -484 to -465 relative to the translation
start site.
Figure 7. Site-directed mutagenesis introduced in either element of DR-8
RARE decreased the promoter activity of pGL2-∆1393. Portion of sequence
of pGL2-∆1393, and those of its mutants pGL2-∆1393 (A). Promoter activity
of pGL2-∆1393 and its mutants was measured under the influence of
500 nM 9cRA (B). Each experiment was repeated at least three times with
identical results. RLU, relative luciferase activity.
Figure 8. Treatment of synthetic retinoic acids increased nuclear expression and specific binding of RAR-β
on the putative RARE. Immunoblot of nuclear extract of H460 cells treated by either 500 nM 9cRA, 1 µM
13cRA, or 1 nM TTNPB showed increased nuclear translocation of RAR-β (A). EMSA revealed specific
binding of RAR-β to the putative DR-8 RARE. Incubation with anti-RAR-β antibody and an unlabelled RARE
competitor led to disappearance of the DNA:protein complex signal; treatment with anti-RXR and
mutated RARE did not (B and C).
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This DR-8 in the human IGFBP-3 promoter is different from
the canonical RARE, represented by DR-1 to DR-5.25 The classical
DR-5 elements are found in the promoters of the RAR-β itself26 and
several Hox and HNF genes.27,28 DR-8 motifs previously identified
in the promoter lesion of human H1 histone and the RAR-β gene
interact with thyroid hormone receptors (TRs), RARs and RXR,
COUP-TF, and v-erbA in a ligand-dependent manner.29,30 In a study
using the DR-8 sequence in the human H1 promoter, COUP-TF,
which usually represses RAREs, enhanced transcriptional activation
through the DR-8. In constrast, v-erbA completely repressed
TR-RXR induction of the H1 gene.29 The pattern of site selectivity
is based on the spacing of DRs(1-5 rule) and polarity of RAR-RXR
complexes.31,32 Among the canonical RAREs, RAR-RXR complex
have preference for DR-1, DR-2, and DR-5 RARE.33 The facts that
expression of RXR-β is suppressed in a large percentage of NSCLC,34
its expression is relatively lower than that of other type of RXRs,35
and as shown in (Fig. 8C), nuclear translocation of RXR-β is not
influenced by 9cRA might be implicated in failure of supershift by
RXR-β antibody. Further studies may be needed to identify appro-
priate partners of RAR-β in heterodimeric complex formation for
binding of DR-8 RARE in IGFBP-3 promoter.
Our study demonstrates that reporter constructs containing DR-8
allowed a several-fold induction of IGFBP-3 promoter activity by
9cRA in the presence of RAR-β. Also, RAR-β binding to the DR-8
was enhanced in the presence of 9cRA. Several signaling pathways
that play important roles during differentiation and cell proliferation
thus influence the rate of IGFBP-3 transcription through a DR-8
response element in its promoter. Mutational analysis suggests that
this site is functionally a DR-8 element for retinoic acid derivatives.
We further demonstrated binding of RAR-β to the DR-8 element in
electrophoretic mobility shift and competition assays between the
RAR consensus sequence and another sequence bound by RAR-β.
Our experiments show that RAR-β is involved in the growth
inhibitory activity of 9cRA via mediation of the induction of
IGFBP-3 expression. Because both IGFBP-3 and RAR-β expression
levels inversely correlate with cell proliferation and are regarded as
putative tumor suppressor genes in NSCLC, our data suggest that
retinoic acids such as 9cRA can influence cell proliferation via regu-
lation of the DR-8 element. By elucidating the linkage mechanism
between IGFBP-3 and RAR-β, our experiments have pinpointed an
intersection between the retinoid and IGF systems. This information
also expands knowledge of the downstream effectors of RAR-β and
suggests how RAR-β might act as a tumor suppressor.
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